Shawn Flanagan, PhD (he/him/his)

VP, Clinical Pharmacology and Early Development
Cidara Therapeutics
San Diego, CA, United States

Shawn Flanagan, PhD, is Vice President of Clinical Pharmacology and Early Development at Cidara Therapeutics, Inc. He is a highly accomplished and influential scientific leader with diverse knowledge of drug development and translational research. Shawn has over 25 years in the Pharmaceutical Industry and over a decade working in the therapeutic area of Infectious Diseases.

Disclosure(s): Cidara Therapeutics: Employee, Salaried Employee, Stocks/Bonds (Public Company), Stocks/Bonds (Public Company)

Presentation(s):

• 319 - Single-Dose and Repeat Single-Dose Ascending Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intramuscular CD388, a Novel Long-acting Drug-Fc Conjugate for Universal Prevention of Seasonal and Pandemic Influenza

  Friday, October 18, 2024
  12:30 PM – 12:35 PM US PT

• 573 - CD388, a Novel Drug-Fc Conjugate (DFC), Demonstrates Prophylactic Activity in an Influenza Human Challenge Model

  Saturday, October 19, 2024
  2:21 PM – 2:39 PM US PT